The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | A myeloma magnifying glass? CD38-targeted Immuno-PET
Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the use of an immuno-PET antibody composed of the native daratumumab labelled with the positron-emitting radionuclide zirconium-89, through the chelator deferoxamine, or 89Zr-DFO-daratumumab, demonstrated successful uptake in osseous deposits in patients with multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
